oa Southern African Journal of Anaesthesia and Analgesia - Dextropropoxyphene is dead? Long live... : guest editorial



On 20 April 2011, the Medicines Control Council (MCC) announced its decision to withdraw all dextropropoxyphene-(DPP-) containing products from the South African market within three months, because of stated safety risks and an insufficiently weighted risk-benefit profile. These risks refer to dose-related cardiac conduction abnormalities associated with QT prolongation, provoked by the main metabolite of DPP, norpropoxyphene.


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error